437 related articles for article (PubMed ID: 11990789)
1. Genetic studies of MIS signalling in sexual development.
Jamin SP; Arango NA; Mishina Y; Behringer RR
Novartis Found Symp; 2002; 244():157-64; discussion 164-8, 203-6, 253-7. PubMed ID: 11990789
[TBL] [Abstract][Full Text] [Related]
2. The müllerian inhibitor and mammalian sexual development.
Behringer RR
Philos Trans R Soc Lond B Biol Sci; 1995 Nov; 350(1333):285-8; discussion 289. PubMed ID: 8570693
[TBL] [Abstract][Full Text] [Related]
3. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
[TBL] [Abstract][Full Text] [Related]
4. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.
Ingraham HA; Hirokawa Y; Roberts LM; Mellon SH; McGee E; Nachtigal MW; Visser JA
Recent Prog Horm Res; 2000; 55():53-67; discussion 67-8. PubMed ID: 11036933
[TBL] [Abstract][Full Text] [Related]
5. Abnormal sexual development in transgenic mice chronically expressing müllerian inhibiting substance.
Behringer RR; Cate RL; Froelick GJ; Palmiter RD; Brinster RL
Nature; 1990 May; 345(6271):167-70. PubMed ID: 2336108
[TBL] [Abstract][Full Text] [Related]
6. Paracrine-mediated apoptosis in reproductive tract development.
Roberts LM; Hirokawa Y; Nachtigal MW; Ingraham HA
Dev Biol; 1999 Apr; 208(1):110-22. PubMed ID: 10075845
[TBL] [Abstract][Full Text] [Related]
7. Müllerian inhibiting substance in reproduction and cancer.
Donahoe PK
Mol Reprod Dev; 1992 Jun; 32(2):168-72. PubMed ID: 1637555
[TBL] [Abstract][Full Text] [Related]
8. Insensitivity to anti-müllerian hormone due to a mutation in the human anti-müllerian hormone receptor.
Imbeaud S; Faure E; Lamarre I; Mattéi MG; di Clemente N; Tizard R; Carré-Eusèbe D; Belville C; Tragethon L; Tonkin C; Nelson J; McAuliffe M; Bidart JM; Lababidi A; Josso N; Cate RL; Picard JY
Nat Genet; 1995 Dec; 11(4):382-8. PubMed ID: 7493017
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
10. The in vivo roles of müllerian-inhibiting substance.
Behringer RR
Curr Top Dev Biol; 1994; 29():171-87. PubMed ID: 7828438
[TBL] [Abstract][Full Text] [Related]
11. Anti-Müllerian hormone receptor defect.
di Clemente N; Belville C
Best Pract Res Clin Endocrinol Metab; 2006 Dec; 20(4):599-610. PubMed ID: 17161334
[TBL] [Abstract][Full Text] [Related]
12. Requirement of Bmpr1a for Müllerian duct regression during male sexual development.
Jamin SP; Arango NA; Mishina Y; Hanks MC; Behringer RR
Nat Genet; 2002 Nov; 32(3):408-10. PubMed ID: 12368913
[TBL] [Abstract][Full Text] [Related]
13. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
14. [Genetics and molecular pathology of anti-Mullerian hormone and its receptor].
Picard JY; Belville C
J Soc Biol; 2002; 196(3):217-21. PubMed ID: 12462075
[TBL] [Abstract][Full Text] [Related]
15. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
16. Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a.
Parr BA; McMahon AP
Nature; 1998 Oct; 395(6703):707-10. PubMed ID: 9790192
[TBL] [Abstract][Full Text] [Related]
17. Testicular anti-Müllerian hormone: history, genetics, regulation and clinical applications.
Josso N; Picard JY; Rey R; di Clemente N
Pediatr Endocrinol Rev; 2006 Jun; 3(4):347-58. PubMed ID: 16816803
[TBL] [Abstract][Full Text] [Related]
18. Molecular biology of MIS and its receptors.
Teixeira J; Donahoe PK
J Androl; 1996; 17(4):336-41. PubMed ID: 8889695
[TBL] [Abstract][Full Text] [Related]
19. Müllerian inhibiting substance as a model for the transforming growth factor-beta family: development of new treatment strategies.
Shah PC; Simpson BB; Donahoe PK
Semin Pediatr Surg; 1996 Aug; 5(3):182-90. PubMed ID: 8858765
[TBL] [Abstract][Full Text] [Related]
20. AMH and AMH receptor defects in persistent Müllerian duct syndrome.
Josso N; Belville C; di Clemente N; Picard JY
Hum Reprod Update; 2005; 11(4):351-6. PubMed ID: 15878900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
